Dr. Todd Morgan

Cure is a term that we just like all of us oncologists just really have a hard time saying because pretty much everybody with a history of cancer, of any kind of cancer, has some risk of that cancer coming back. And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but

Cure is a term that we just like all of us oncologists just really have a hard time saying because pretty much everybody with a history of cancer, of any kind of cancer, has some risk of that cancer coming back. And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but

Cure is a term that we just like all of us oncologists just really have a hard time saying because pretty much everybody with a history of cancer, of any kind of cancer, has some risk of that cancer coming back. And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but

Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test, PSA, which is... despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test, PSA, which is... despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test, PSA, which is... despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

Hey, Aditya. So awesome to be here. Thank you. Thank you. Thank you.

Hey, Aditya. So awesome to be here. Thank you. Thank you. Thank you.

Hey, Aditya. So awesome to be here. Thank you. Thank you. Thank you.

Oh, wait, wait. So tell me about that. I missed it. Where is it published?

Oh, wait, wait. So tell me about that. I missed it. Where is it published?

Oh, wait, wait. So tell me about that. I missed it. Where is it published?

That's awesome. That's a great idea for a study. Really, really good. I can't wait to see it.

That's awesome. That's a great idea for a study. Really, really good. I can't wait to see it.

That's awesome. That's a great idea for a study. Really, really good. I can't wait to see it.

Yeah, it's awesome. I mean, pretty amazingly early in my career, I think, thanks to some phenomenal mentors that I've had, I had the opportunity to participate in some different AUA and ASCO guideline panels and NCCN. And I, you know, surprised how much I enjoy that process, you know. It is meaningful.

Yeah, it's awesome. I mean, pretty amazingly early in my career, I think, thanks to some phenomenal mentors that I've had, I had the opportunity to participate in some different AUA and ASCO guideline panels and NCCN. And I, you know, surprised how much I enjoy that process, you know. It is meaningful.